REGULATION OF COST-EFFECTIVENESS THRESHOLDS IN HEALTHCARE: LEGAL FRAMEWORK AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Cost-effectiveness thresholds are decision-making benchmarks used to determine whether the additional cost of a medicine, medical device, diagnostic test, or public health intervention is justified by the additional health benefits it produces. They are central to health technology assessment (HTA), reimbursement decisions, pharmaceutical pricing, and the allocation of limited public healthcare resources.

A common measure is the incremental cost-effectiveness ratio (ICER), calculated by dividing the additional cost of a new intervention by its additional health benefit, commonly measured in quality-adjusted life years (QALYs). However, a threshold should not operate as an inflexible rule. Decisions must also consider clinical effectiveness, affordability, disease severity, uncertainty, equity, and the consequences for patients who may lose access to other healthcare services.

2. LEGAL AND REGULATORY FRAMEWORK

A. INDIA

The Department of Health Research operates Health Technology Assessment in India (HTAIn), which evaluates the clinical effectiveness, cost-effectiveness, safety, equity, and other relevant aspects of healthcare interventions. Its assessments inform government policy, healthcare procurement, and resource-allocation decisions.

The Indian Reference Case for economic evaluation provides methodological recommendations concerning comparators, costs, health outcomes, time horizons, discounting, uncertainty, and equity. Importantly, it states that India does not currently have a formally recognised national cost-effectiveness threshold. One-time GDP per capita may be used as an analytical reference in the absence of a formally determined threshold, but it should not be treated as a binding legal funding rule.

Article 21 of the Constitution, as interpreted by the Supreme Court, protects life and personal liberty and supports the recognition of healthcare-related rights. Articles 14 and 21 are relevant when public authorities make healthcare funding decisions that must be rational, fair, and consistent with applicable law. However, these constitutional provisions do not establish a particular monetary threshold per QALY.

B. UNITED KINGDOM

The National Institute for Health and Care Excellence (NICE) uses cost-effectiveness analysis to inform decisions concerning NHS treatments. Its conventional appraisal framework has generally regarded an ICER below £20,000 per QALY as favourable, while decisions above that level require additional consideration. The relevant approach is not simply a mechanical pass-or-fail test; uncertainty, innovation, health benefits, and other specified factors can influence recommendations.

C. INTERNATIONAL PRINCIPLES

The World Health Organization has cautioned against treating the historical one-to-three-times GDP-per-capita approach as an automatic decision rule. Appropriate thresholds should reflect the health benefits forgone when resources are allocated elsewhere, alongside affordability, fairness, feasibility, and local healthcare priorities.

3. PRINCIPLES GOVERNING THRESHOLD REGULATION

A. TRANSPARENCY: Authorities should publish assessment methods, evidence requirements, decision criteria, and reasons for departures from established benchmarks.

B. EVIDENCE-BASED DECISION-MAKING: Thresholds should be informed by reliable clinical evidence, appropriate economic models, and sensitivity analyses that disclose uncertainty.

C. EQUITY AND NON-DISCRIMINATION: Decisions should examine whether a uniform threshold disadvantages people with rare diseases, disabilities, severe illnesses, or limited access to treatment.

D. AFFORDABILITY AND OPPORTUNITY COST: A treatment may be cost-effective but still unaffordable at population scale. Decision-makers should assess both value for money and the health benefits sacrificed by diverting funds from alternative services.

E. ACCOUNTABILITY: Public authorities should explain material decisions, apply relevant policies consistently, and provide appropriate review or appeal mechanisms.

4. IMPORTANT CASE LAWS

1. R (Eisai Ltd) v. NICE, [2008] EWCA Civ 438 — Direct authority on judicial review of cost-effectiveness appraisal.

The English Court of Appeal considered NICE's assessment of Alzheimer's disease medicines and its economic appraisal framework. The litigation illustrates the importance of lawful methodology, adequate reasoning, and procedural fairness when a public authority evaluates the cost-effectiveness of healthcare technologies. It does not establish that a particular ICER must always be accepted.

2. R (Servier Laboratories Ltd) v. NICE, [2009] EWHC 281 (Admin) — Direct authority on NICE's appraisal framework.

The High Court examined a challenge involving NICE's appraisal of medicines. The case illustrates how courts assess the legality of technical appraisal decisions without simply replacing the expert body's economic judgment with their own. Cost-effectiveness methodology must operate within the applicable legal and procedural framework.

3. R (Rogers) v. Swindon Primary Care Trust, [2006] EWCA Civ 392 — Direct authority on healthcare funding decisions.

The Court of Appeal held that the funding policy concerning Herceptin was irrational in its particular circumstances because the authority's approach lacked a rational basis for distinguishing between clinically eligible patients. The case demonstrates that resource-allocation decisions must be logically justified and consistently applied. It did not establish a universal cost-per-QALY threshold.

4. R (Condliff) v. North Staffordshire Primary Care Trust, [2011] EWHC 872 (Admin) — Direct authority on individual healthcare funding policies.

The High Court examined a challenge to the refusal of funding for gastric bypass surgery. The judgment illustrates the importance of lawful individual funding policies, rational eligibility criteria, and fair treatment of comparable applicants. It also recognises the difficult choices public authorities must make when healthcare resources are limited.

5. R v. Cambridge Health Authority, ex parte B, [1995] 1 WLR 898 — Analogous authority on resource allocation.

The English Court of Appeal considered the limits of judicial intervention in decisions about expensive medical treatment. The case recognises that healthcare authorities cannot necessarily provide every treatment requested, regardless of cost, and that courts must consider the institutional and financial constraints affecting public services.

6. Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647 — Analogous Indian authority on precaution and sustainable decision-making.

The Supreme Court recognised the precautionary principle and polluter pays principle in environmental law. Although the case did not concern healthcare thresholds, its broader reasoning supports decisions grounded in evidence, precaution, and the responsible management of limited resources. It should not be cited as direct authority for a monetary healthcare threshold.

5. PRACTICAL REGULATORY AND COMPLIANCE REQUIREMENTS

Regulators and health technology assessment bodies should establish clear methods for selecting comparators, measuring health outcomes, estimating costs, and evaluating uncertainty. Economic submissions should disclose assumptions, data sources, conflicts of interest, and sensitivity analyses.

Authorities should separately assess the ICER, total budget impact, distributional consequences, and the opportunity cost of funding a new intervention. Exceptional funding arrangements should have published criteria and safeguards against arbitrary or discriminatory decisions. Periodic review is also necessary when medicine prices, clinical evidence, or available healthcare resources change.

6. CONCLUSION

Cost-effectiveness thresholds are important instruments for promoting rational and equitable healthcare resource allocation, but they should not be treated as automatic legal prohibitions or guarantees of funding. Indian law currently relies on health technology assessment and broader legal principles rather than a formally recognised national monetary threshold. Judicial decisions, particularly those concerning NICE and NHS funding, demonstrate that public authorities must use rational criteria, follow fair procedures, and explain their decisions. A sound regulatory framework must combine economic evidence with affordability, equity, clinical need, transparency, and accountability.